263 related articles for article (PubMed ID: 15080079)
1. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.
Barlési F; Gimenez C; Torre JP; Doddoli C; Mancini J; Greillier L; Roux F; Kleisbauer JP
Respir Med; 2004 Apr; 98(4):357-62. PubMed ID: 15080079
[TBL] [Abstract][Full Text] [Related]
2. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.
Pujol JL; Boher JM; Grenier J; Quantin X
Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401
[TBL] [Abstract][Full Text] [Related]
3. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
5. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
[TBL] [Abstract][Full Text] [Related]
6. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
7. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
8. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
[TBL] [Abstract][Full Text] [Related]
9. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of serum tumor markers in patients with lung cancer.
Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
12. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
13. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Massaron S; Cataldo I; Oldani S; Iurlo A; Caldiera S; Bombardieri E
Int J Biol Markers; 1999; 14(2):92-8. PubMed ID: 10399628
[TBL] [Abstract][Full Text] [Related]
14. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
15. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score.
Blankenburg F; Hatz R; Nagel D; Ankerst D; Reinmiedl J; Gruber C; Seidel D; Stieber P
Tumour Biol; 2008; 29(4):272-7. PubMed ID: 18781099
[TBL] [Abstract][Full Text] [Related]
16. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
17. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
18. [Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival].
Załeska M; Szturmowicz M; Zych J; Roszkowska-Sliz B; Demkow U; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2010; 78(1):14-20. PubMed ID: 20162514
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer.
Giovanella L; Ceriani L; Bandera M; Beghe B; Roncari G
Int J Biol Markers; 1995; 10(3):156-60. PubMed ID: 8551058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]